Mologen cancer, infectious news

Mologen will reduce headcount by 17 (26%) to 49 and focus on developing lead product lefitolimod ( MGN1703), a toll-like receptor 9 (TLR9) agonist based on double Stem Loop Immunomodulator

Read the full 302 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE